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Associations between follow-up screening after
gestational diabetes and early detection of
diabetes – a register based study
Christinna Rebecca Olesen*†, Jane Hyldgaard Nielsen†, Rikke Nørmark Mortensen, Henrik Bøggild,
Christian Torp-Pedersen and Charlotte Overgaard
Abstract
Background: Women whose pregnancy was complicated by gestational diabetes have a 7-fold higher risk of
developing diabetes, primarily type 2. Early detection can prevent or delay the onset of late complications, for
which follow-up screening is important. This study investigated the extent of participation in follow-up screening
and the possible consequences of nonattendance in the Region of North Jutland, Denmark.
Method: In Danish national registers covering the years 1994–2011 we identified 2171 birthing women whose
pregnancy was complicated by first-time gestational diabetes. Control visits to general practitioners and biochemical
departments after giving birth were charted. Following national guidelines we defined four intervals for assessment of
participation in follow-up screening. Diagnosis of diabetes or treatment with glucose-lowering agents after giving
birth were also identified. Participation in follow-up screening and risk of diabetes was calculated. Time to obtaining
diagnosis of diabetes or initiating treatment was analysed by Cox regression models. All models were adjusted for
age, ethnicity and income.
Results: High attendance was found during the first control interval, after which attendance decreased with time after
giving birth for both controls at general practitioners and biochemical departments. All differences in proportions
were statistically significant. Women attending controls at general practitioners had a significantly higher risk of
diabetes diagnosis and treatment after gestational diabetes than women not attending. The results for women
attending testing at biochemical departments also showed an increased risk of initiation of treatment. Women
attending at least one general practitioners control had a significantly higher risk of early diabetes diagnosis or
treatment. Time to initiation of treatment was significantly higher for testing at biochemical departments. Women
with high incomes had a significantly lower risk of diabetes diagnosis or initiation of treatment compared to
low-income women.
Conclusion: Participation in follow-up screening after gestational diabetes is low in the North Denmark Region.
Follow-up screening ensures early detection of diabetes and initiation of treatment. Our results emphasize the
importance of development of interventions to improve early detection and prevention of diabetes after gestational
diabetes.
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Background
Women affected by gestational diabetes have a 7-fold
higher risk of diabetes compared to women with normo-
glycaemic pregnancies, with the most rapid increase in
type 2 diabetes found during the first five years after giving
birth [1,2]. Diabetes can have serious health implications
[3], such as retinopathy, neuropathy and cardiovascular
heart disease [4]. Early detection of type 2 diabetes can
prevent or delay the onset of late complications [1,3].
International as well as national guidelines recommend
follow-up screening with either oral glucose tolerance
tests or fasting plasma glucose tests after pregnancy com-
plicated by gestational diabetes [5,6]. The participation
levels for follow-up screenings reported in the literature
ranging from 14 to 61%, are unsatisfying [7]. Various rea-
sons for nonattendance have been found, such as clini-
cians’ unawareness of the screening offer and women
choosing not to participate [8-10]. Cross-national diffe-
rences in the organization of healthcare systems compli-
cate the applicability of international strategies to increase
follow-up screening after gestational diabetes to other
healthcare contexts [11]. Public health is compromised by
the existence of the pathway from gestational diabetes to
type 2 diabetes, which accounts for considerable costs in
the healthcare sector [4]. Gestational diabetes may be one
of the factors underlying the increasing prevalence of type
2 diabetes worldwide, of which it is considered a valid in-
dicator [3]. Even though the incidence of gestational dia-
betes is low in Denmark and the other Scandinavian
countries, affecting 2–3% of all pregnancies, the preven-
tive potentials of follow-up screening for type 2 diabetes
are considerable [1]. A better understanding of the associ-
ation between screening after gestational diabetes and the
subsequent risk of type 2 diabetes is necessary to deter-
mine the importance of the screening. Studies regarding
participation in follow-up screening in a European context
such as Denmark are lacking, which emphasises the im-
portance of this study. The aim of this study was to exam-
ine the extent of participation in follow-up screening in
The North Denmark Region, and the possible consequen-
ces of nonattendance.
Methods
Design and setting
A register-based study of gestational diabetes among in-
habitants in The North Denmark Region, from 1 January
1994 to 31 December 2011. The administrative Region
encompasses around 580.886 inhabitants [12], and as in
the rest of Denmark, the health care system is centered
around general practitioners [13]. The access to the health
care system is free of charge [13]. Denmark’s permanent
and unique civil registration number enabled the linkage
of individual data across multiple nation-wide registers,
known to encompass virtually all inhabitants [14].
Data sources
The data registers were linked in Statistics Denmark
based on the civil registration number. The National Pa-
tient Register holds data on all hospital admissions in
Denmark [15]. The classification system contains codes
that allows the tracing of data associated to specific health
care services or diagnoses (International Classification of
Diseases, ICD-10), which enabled us to obtain the data
relevant for our purposes [16]. The study population
was included by the coincidence of birth (ICD-10 codes:
D080-D084) [16] and first-time gestational diabetes diag-
nosis (ICD-10 code: D0244) [16] and/or other diabetes
diagnosis (ICD-10 codes: DE10-14) [16] before, during
and after pregnancy and birth. Data regarding population
characteristics were obtained from the same register. Gen-
eral practitioners are not obliged to register diagnoses in
their clinics. Income data were obtained from the Danish
Income Statistics Register [14]. The Danish National Pre-
scriptions Registry contains data on all claimed prescrip-
tions from Danish pharmacies [14], and might thus serve
as a proxy measure of diabetes. The identification of all
claimed prescriptions on glucose-lowering agents (ATC-
code: MA10) was enabled by WHO’s ATC classification
(Anatomical therapeutic chemical classifications system)
[17]. Data from the National Health Service Register [13]
enabled the monitoring of the follow-up screening of
women whose pregnancy was complicated by first-time
gestational diabetes, as general practitioners can perform
and analyse oral glucose tolerance tests [18], which are
paid by the Health Service. The code for general practi-
tioners testing of blood glucose and/or oral glucose toler-
ance is the same and was used to identify women who had
received follow-up screening (Code: 7136) [18,19]. Data
on all blood samples examined at biochemical depart-
ments in the region were obtained to identify women with
first-time gestational diabetes who had an oral glucose tol-
erance test or a fasting plasma glucose test performed
since 2006 (Codes: NPU21530; NPU02195) respectively
[20]. Both tests are used in the follow-up screening of
women with prior gestational diabetes [5]. The NPU
terminology (Nomenclature for Properties and Units
terminology) is an international coding system that en-
ables identification and communication of the results
from clinical laboratories in the health sector [21].
Data and measurement
For verification of the gestational diabetes (ICD-10 code:
DO244) diagnosis, all collected data regarding other dia-
betes diagnosis (ICD-10 codes: DE10-14) and claimed pre-
scriptions on glucose-lowering agents (ATC-code: MA10)
were divided into three subgroups: prior to pregnancy,
during pregnancy and after pregnancy. We thus excluded
women who had been diagnosed with any type of dia-
betes and/or treated with glucose-lowering agents prior to
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pregnancy. Furthermore, exclusion was performed due to
the suspicion of underlying unregistered diabetes prior to
pregnancy. Claimed prescriptions or a diagnosis within a
year after giving birth is known to be related to gestational
diabetes and did not lead to exclusion. This approach has
been validated in the literature [22]. Women with gesta-
tional diabetes that required diet and/or medical treat-
ment were included in the study, despite of their different
risk of diabetes after gestational diabetes [6]. International
and national guidelines recommend that all women with
gestational diabetes-complicated pregnancies participates
in follow-up screening 6–8 weeks after giving birth and
thereafter at least biannually [5,6]. Time to control and
testing by general practitioners and at biochemical depart-
ments were divided into four intervals, defined in accor-
dance with national guidelines [5]. The time ranges for
the intervals of follow-up screening at general practitio-
ners and biochemical departments were two years; how-
ever, for the last control at biochemical departments a
range of approximately four years was constructed. The
interval for the first control at general practitioner was
0–3 months after giving birth, for the first control at
biochemical departments 0–5 months after giving birth.
From this point on the controls will be described as
Control 1,2,3,4 for participation at both general practi-
tioners and biochemical departments. Inclusion in the
four controls was not conditioned by attendance in any
of the other follow-up screening controls. Broad inter-
vals for biochemical department testing were constructed
to ensure detection of all women referred from their gen-
eral practitioner to testing at biochemical departments.
The referrals were necessitated by the fact that not all gen-
eral practitioners perform oral glucose tolerance tests at
their clinics. From one year after giving birth we inves-
tigated associations between participation in follow-up
screening and diabetes diagnosis/treatment with glucose-
lowering agents. A time variable was created to analyse as-
sociations between attending at least one control and time
to diabetes diagnosis or treatment. The variable was based
on time from giving birth to obtaining a diagnosis of dia-
betes or initiation of treatment, until the time limit of the
register available or censuring due to next pregnancy/birth
or death, whichever occurred first. Data on age and in-
come were divided into tertiles and included as categorical
variables. Income was included as a possible confounder
since low income is associated with a higher prevalence of
diabetes [23]. Income was consumer-indexed (2009), and
determined based on data from the year before birth, to
ensure the best possible representation of the women’s so-
cioeconomic status. Age was also included as a possible
confounder since older women have a higher risk of de-
velopment of diabetes after gestational diabetes [6]. To
allow for differences in the risk of developing type 2 dia-
betes, three ethnicity categories were created: Caucasian
(Danish/other), Asian/Middle Eastern, and African [6,24].
The categories were constructed because women with
Asian, Middle Eastern and African ethnicity has different
risks of developing both gestational diabetes and diabetes
than Caucasian women [6,24]. The three variables were
included to control for possible confounding regarding
diabetes diagnosis or treatment.
Outcomes
The primary outcome was attendance in follow-up screen-
ing at general practitioners or biochemical departments
after gestational diabetes in each of the defined time in-
tervals. The outcome was defined by coding of an oral
glucose tolerance test or a fasting plasma glucose test.
The secondary outcome was the risk of and time to dia-
betes diagnosis or treatment with glucose-lowering agents
among participants and non-participants. Outcomes were
predefined.
Statistical analyses
The study applied descriptive statistics (N/%) to illus-
trate the distribution of age, income and ethnicity. All
models were adjusted for these variables. Participation
in follow-up screening was analysed using chi-squared
tests. Women appearing as missing in the tables were ei-
ther excluded or censured by death, second birth or end
of registration. To determine the association between
participation in follow-up screening and diabetes-related
outcomes, we applied logistic regression models presented
with odds ratios (OR) and 95% confidence intervals (CI).
We furthermore examined possible confounding by age,
income and ethnicity and interactions between ethnicity
and income, and between age and income. Cox’s propor-
tional hazard models were applied to investigate the haz-
ard ratio (HR) of diabetes related outcomes, depending on
participation in at least one general practitioner or bio-
chemical department control. All Cox proportional hazard
models met the proportional hazard assumption. The SAS
statistical software package for Windows, version 9.2, was
used (SAS Institute, Cary, NC, USA).
Ethics
Register based observational studies do not require ethical
approval in Denmark [25]. The Danish Data Protection
Agency approved this study (No. 2007-41-1667).
Results
Participant characteristics
A total of 149.903 women in The North Denmark Region
gave birth during the study period, 2238 of whom had
a diagnose of first-time gestational diabetes. Diagnosis
of diabetes and/or treatment with glucose-lowering agents
prior to pregnancy lead to the exclusion of 67 women. The
final study population included 2171 women (Figure 1). As
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shown in Table 1 the study population had a mean age of
30.9 years and the mean number of births at the time of
first gestational diabetes diagnosis was 1.6. Baseline charac-
teristics on income, ethnicity and age are also listed in
Table 1. Among the women in the Region 1.4% had first-
time gestational diabetes during the time period.
Participation in follow-up screening
Table 2 shows the participation in follow-up screening.
Participation decreased with time after giving birth. The
proportion of women attending Control 1 at their general
practitioner after giving birth was 80.5%, 47.3% attended
Control 2, 29.1% Control 3 while 17.7% attended Control
4. For controls conducted at biochemical departments, the
proportion of women attending decreased from 10.2% at
Control 1 to 0.5% at Control 4. Significant differences
were found for all proportions regarding attendance and
non-attendance, with p-values under the 5% significance
level (Table 2). The number of women categorized as
missing increased primarily due to the occurrence of a
subsequent pregnancy. Of the 2171 women in the study,
88 (4.1%) had treatment-requiring gestational diabetes
(not shown in tables). One-hundred and twenty-four
(5.8%) were subsequently diagnosed with diabetes and 229
(11%) claimed prescriptions on glucose-lowering agents
after giving birth (Table 2). To estimate undiagnosed dia-
betes among non-participants, we applied the mean num-
ber of diabetes diagnosis among the participants; yielding
an estimated 119 non-attenders to general practitioner
controls and 509 non-attenders to biochemical depart-
ments with undiagnosed diabetes (not shown in tables).
Logistic regression analysis results showed a statistical
significant positive association between attendance at
general practitioner controls and receiving a diagnosis of
diabetes and initiation of treatment with glucose-lowering
agents after gestational diabetes (Tables 3 and 4). The low-
est risk applied to Control 1 for diabetes diagnosis (OR
2.4; 95% CI 1.3-4.4) and the highest risk applied to Con-
trol 4 for diabetes diagnosis (OR 11.8; 95% CI 7.7-18.0)
(Tables 3). Associations between diagnosis of diabetes and
follow-up screening at biochemical departments were in-
significant for all controls (Table 3).
The lowest risk also applied for Control 1 for treat-
ment outcomes (OR 2.3; 95% CI 1.5-3.5) the highest risk
applied for Control 4 for treatment (OR 8.9; CI 95%
6.5-12.2) (Tables 4). A significant positive association
between testing at a biochemical department and treat-
ment with glucose-lowering agent was also detected, with
Women given birth in RN for the
time period
N =149903
Women with first time
gestational diabetes
N = 2238
Women receiving any diabetes  
diagnoses before pregnancy 
were excluded
N = 14
Women who claimed prescriptions 
on glucose-lowering agents before
pregnancy were excluded
N = 3
Women with diabetes diagnoses
and claimed prescriptions on 
glucose-lowering agents before
pregnancy were excluded
N = 50
Final study population
N = 2171
Figure 1 Flowchart.
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the lowest values applying for Control 1 (OR 2.9; 95% CI
1.6-5.3) and the highest for Control 4 (OR 8.7; 95% CI
1.5-49.4). However, the association was insignificant
for Control 3 (Table 4). Confidence intervals (Tables 3
and 4) widely increased with time, due to the decreasing
attendance at either type of testing place.
The forest plots in Figure 2 illustrates the risk of dia-
betes diagnosis or initiation of treatment. Income was a
confounding factor, with a negative association between
income and diagnosis of diabetes (not shown in tables).
Women with the highest incomes had a statistically sig-
nificant lower risk of being diagnosed with diabetes (OR
0.6; 95% CI 0.4-0.9) or of being treated with glucose-
lowering agents (OR 0.6; 95% CI 0.5-0.9) compared to
women with the lowest income. No interaction between
ethnicity and income, or between ethnicity and age, was
detected.
Results of the Cox regression analysis showed statisti-
cally significant positive associations between attendance
to at least one control at either a general practitioner or
a biochemical department and time to receiving a diabetes
diagnosis or initiation of treatment (Table 5). Women at-
tending at least one general practitioner control had a
higher risk of diabetes diagnosis (HR 2.7; 95% CI 1.1-5.9)
or treatment with glucose-lowering agents (HR 2.1;
95% CI 1.2-3.5) compared to women who did not attend
either of the controls. The risk of treatment with glucose-
lowering agents was also higher for women attending only
Table 2 Follow-up screening participation after gestational diabetes in the Region in the period 1994-2011
Follow-up screening Diabetes women (N = 124) Treatment women (N = 229)
Control +
N (%)
Control –
N (%)
Missing
N (%)*
p Control +
N
Control –
N
p Control +
N
Control –
N
p
General practitioner
(N = 2171)
Control 1: Within 3
months after birth
1744 (80.5) 423 (19.5) 41 (0.2) <0.001 112 12 0.0045 205 24 0.0002
Control 2: 3 months
to 2 years
852 (47.3) 950 (52.7) 369 (17.0) 0.0210 108 16 <0.0001 188 37 <0.0001
Control 3: 2 years to
4 years
526 (29.1) 1281 (70.9) 364 (16.8) <0.001 94 27 <0.0001 152 62 <0.0001
Control 4: 4 years to
6 years
333 (17.7) 1551 (82.3) 287 (12.8) <0.001 75 37 <0.0001 116 89 <0.0001
Biochemical unit**
(N = 1218)
Control 1: Within 6
months after birth
111 (10.2) 979 (89.8) 128 (10.5) <0.001 113 10 0.4932 181 40 <0.0001
Control 2: 6 moths
to 2.4 years
69 (6.4) 1013 (93.6) 136 (11.2) <0.001 113 10 0.8829 184 36 <0.0001
Control 3: 2.4 years
to 4.5 years
29 (2.5) 1116 (97.5) 73 (6.0) <0.001 113 9 0.3085 192 28 <0.0001
Control 4: 4.5 years
to 8.2 years
6 (0.5) 1190 (99.5) 22 (1.8) <0.001 115 5 0.7766 198 22 <0.0001
*Women appearing as missing in the table were censured by either new pregnancy or birth and death.
**Data on blood samples at biochemical departments are only available for women giving birth after 2006.
Table 1 Population characteristics
Variables N (%)
Women 2171 (100)
Age*
Young 717 (33)
Middle 716 (33)
Older 738 (34)
Income**
Low 715 (33)
Middle 714 (33)
High 715 (34)
Ethnicity
Caucasian (Danish/other) 1981 (92.3)
Asian/middle eastern 128 (5.9)
African 61 (2.8)
Mean SD
Birth of diagnosis 0.8
1.6
Age 5.0
30.9
*Age categorized as tertiles: Young: <=29.7 Middle: >29.7.
<=33.9 and older > 33.9.
**Income categorized as tertiles (Dk.kr.) Low: <=292.872.
Middle: >292.872 and < =395.691 High: >395.691.
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one control at a biochemical department (HR 2.1; 95% CI
1.2-3.6). Values for the risk of diabetes diagnosis for the
women attending a biochemical department did not reach
the significance level (Table 5). High-income women had
a significantly shorter time to diabetes diagnosis (HR 0.6;
95% CI 0.4-0.9) or treatment (HR 0.7; 95% CI 0.5-0.9)
compared to women with the lowest incomes (not shown
in tables). The association between time to diabetes or
treatment was not influenced by interaction.
Discussion
This study shows low participation in follow-up screen-
ing after gestational diabetes that are recommended in
international and national guidelines [5,6]. The study of
2171 women with first-time gestational diabetes showed
significantly decreasing participation in follow-up scree-
ning, from 80.5% at Control 1 to 17.7% of the women
visiting their general practitioner for Control 4. Even
lower attendance was found for biochemical departments,
with 10.2% at Control 1 and 0.5% attending Control 4.
The risk of a diabetes diagnosis was strongly associated
with participation in follow-up screening, with an 11.8-
fold increased risk for women attending general practi-
tioner Control 4. Attenders at Control 4 had an increased
risk of initiation of treatment with glucose-lowering agents
at 8.9-fold and 8.7-fold for general practitioner and bio-
chemical department controls, respectively. Women who
attended at least one general practitioner control more-
over had a 2.7-fold increased risk of shorter time to dia-
betes diagnosis. This also applied for the initiation of
treatment, with a 2.1-fold increase in the risk for either
type of control. The high risk of diabetes diagnosis and
initiation of treatment among women attending the con-
trols emphasizes that attendance enables early detection
of diabetes, which can prevent the development of late
complications [1,3].
Strengths and limitations
The strength of this study is its basis in the complete
and comprehensive data held by the Danish national
registers and the negligible risk of loss to follow-up
[14,26]. The structure of the Danish health care system
and the possibility to include both hospital and general
practitioners, as well as both register based diagnosis
and initiated treatment allows a full follow-up on a large
cohort. The defined intervals were furthermore sufficiently
broad to ensure the detection of women who participated
in follow-up screenings, whether at their general practi-
tioner or at biochemical departments. The limitations of
the study relates to the validity problems in connection
with the regionally based blood sample registration, since
this serves purely administrative purposes. We are un-
aware of any validity studies of on the regional blood
sample registration. Our results on the proportion of
women having tests performed at Control 1 are consi-
derably higher than those found in comparable studies
[7,8,11,27]. However, data on blood sampling have only
been available since 2006, which has limited the analysis
of testing at biochemical departments to women giving
birth after that time. The insignificant results obtained for
diagnosis of diabetes as outcome may be caused by the
limited data. The problem of under-registration of dia-
betes diagnosis was caused by the fact that not all women
in treatment with glucose-lowering agents had a registered
diabetes diagnosis. Inaccuracies in coding procedures may
have led to the problematic validity of diabetes diagnosis
registered in the National Patient Register [28]. However,
the National Patient Register enabled detailed information
Table 3 Association between participation in follow-up
screening and diabetes diagnosis
Crude OR
(95% CI)
Adjusted*
OR (95% CI)
General practitioner
Control 1: Within 3 months after birth 2.4(1.3-4.3) 2.4 (1.3-4.4)
Control 2: 3 months to 2 years 8.6 (5.1-14.7) 8.3 (4.8-14.1)
Control 3: 2 years to 4 years 10.1 (6.5-15.7) 9.8 (6.2-15.3)
Control 4: 4 years to 6 years 11.9 (7.9-18.0) 11.8 (7.7-18.0)
Biochemical unit**
Control 1: Within 6 months after birth 1.4 (0.4-4.9) 0.9 (0.2-4.1)
Control 2: 6 months to 2.4 years 2.4 (0.7-8.2) 1.5 (0.3-6.9)
Control 3: 2.4 years to 4.5 years 4.3 (0.9-19.2) 1.7 (0.2-14)
Control 4: 4.5 years to 8.2 years*** - -
Women with onset of new pregnancy/birth or occurrence of death were
excluded from the analysis.
*Adjusted for income, age and ethnicity.
**Data on blood samples are only available for women giving birth after 2006.
***To few events.
Table 4 Associations between participation in follow-up
screening and treatment with glucose lowering agents
Crude OR
(95% CI)
Adjusted*
OR (95% CI)
General practitioner
Control 1: Within 3 months after birth 2.2 (1.5-3.5) 2.3 (1.5-3.5)
Control 2: 3 months to 2 years 7.4 (5.1-10.6) 7.1 (4.9-10.3)
Control 3: 2 years to 4 years 8.1 (5.9-11.2) 8.1 (5.9-11.3)
Control 4: 4 years to 6 years 8.8 (6.5-12.1) 8.9 (6.5-12.2)
Biochemical unit**
Control 1: Within 6 months after birth 3.1 (1.7-5.5) 2.9 (1.6-5.3)
Control 2: 6 months to 2.4 years 3.8 (2.0-7.3) 3.5 (1.8-6.9)
Control 3: 2.4 years to 4.5 years 3.3 (1.2-8.9) 2.5 (0.8-7.4)
Control 4: 4.5 years to 8.2 years 7.9 (1.4-43.8) 8.7 (1.5-49.4)
Women with onset of new pregnancy/birth or occurrence of death were
excluded from the analysis.
*Adjusted for income, age and ethnicity.
**Data on blood samples are only available for women giving birth after 2006.
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regarding hospital admissions in Denmark and further de-
scription of the register can be obtained from Lynge et. al.
[28]. The detailed information of the National Prescription
Registry, however, enabled us to detect women in diabetes
treatment who were not registered with a diabetes diagno-
sis. Further information regarding the National Prescrip-
tion registry can be obtained from Kildemoes et. al. [26].
As described earlier, type 2 diabetes is the more frequent
diabetes type among women with previous gestational dia-
betes [26]. We expected that the majority of the diagnosed
women had received a type 2 diabetes diagnosis. The dia-
betes outcome category contains all diagnosis of diabetes,
which strengthens the validity of our study and prevented
us from excluding women diagnosed with diabetes after
gestational diabetes. The use of the National Health Ser-
vice Register may also have caused validity problems, al-
though we are unaware of any relevant studies regarding
this matter. Further description regarding this register can
be obtained from Andersen et. al. [13]. Despite the strong
economic incentives, the misreporting of minor additional
laboratory services in particular, may occur since fees for
these services are small [13]. Whether the general prac-
titioner performed oral glucose tolerance tests or blood
glucose tests cannot be ascertained, as the codes used to
detect follow-up screening are the same [18,19]. General
practitioners who are unable to perform or analyse oral
glucose tolerance tests can refer the women or have the
test performed by a biochemical department. However,
80.5% of the women were registered as having a test per-
formed at Control 1, which indicates a predominantly cor-
rect coding. A further limitation of this study concerns the
possible demographic selection bias related to its basis in
the relatively deprived North Denmark Region [12,29]. A
higher proportion of socioeconomically disadvantaged
women in our population may have led to an overes-
timated risk of diabetes related outcomes in relation to
non-attendance in follow-up screening, since socioeco-
nomic status is a determinant for diabetes [23]. Results re-
garding the risk of diabetes can be higher in our study
population, and the relatively high risks have to be in-
terpreted with caution. However a previous mentioned
meta-analysis finds the risk of diabetes among women
with pregnancy complicated by gestational diabetes, 7-fold
higher compared to women with normoglycaemic preg-
nancies [1]. Only at the later controls our risk estimates
exceeds the risk found in the meta-analysis.
Interpretation
While we found high participation rates in the first control
after gestational diabetes, other studies have reported rates
Figure 2 Risk of diabetes diagnosis or treatment for control at general practitioner or biochemical department*. *Adjusted for income,
age and ethnicity. Data on blood samples are only available for women giving birth after 2006. **To few events. Women with onset of new
pregnancy/birth or occurrence of death were excluded from the analysis.
Table 5 Association between risk-time to diabetes diagnosis or treatment at minimum one control
Diabetes Treatment
N Crude Adjusted N Crude Adjusted
HR (95% CI) HR (95% CI)* HR (95% CI) HR (95% CI)
Min. 1 control at general practitioner (n = 2123) 124/2123 2.6 (1.15-5.9) 2.7 (1.1-5.9) 229/2089 2.1 (1.2-3.5) 2.1 (1.2-3.5)
Min. 1 control at a biochemical unit** 22/1211 1.1 (0.3-3.9) 0.8 (0.1-3.3) 77/1202 2.2 (1.3-3.8) 2.1 (1.2-3.6)
Women with onset of new pregnancy/birth or occurrence of death were excluded from the analysis.
*Adjusted for income, age and ethnicity.
**Data on blood samples are only available for women giving birth after 2006.
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varying from 14 to 61% for this control. A recent review
also finds that screening for diabetes after gestational dia-
betes generally is low [30]. However, those studies were
restricted to the first control [11]. Organisational differ-
ences between health care sectors effects the compa-
rability with results from other health care contexts.
Attendance varied greatly for testing at first control, with
80.5% and 10.2% for general practitioners and biochemical
departments, respectively. The majority of results retained
significant levels, however the limited data on blood sam-
ples may have caused insignificant associations between
controls at biochemical departments and diagnosis of dia-
betes and treatment at Control 3. A likely reason for the
high participation in the first general practitioner control
after giving birth is that this examination is part of a
standard postpartum visit [31]. General practitioner con-
trols had higher attendance than biochemical department
controls, possibly because some practitioners are capable
of performing the oral glucose tolerance test. However,
other regions recommend that the tests are analysed or
performed only by biochemical departments because of
the varying quality of the general practitioners equipment
[32]. Low participation in follow-up screening can be re-
lated to healthcare providers, health systems and pa-
tient barriers. Barriers related to healthcare systems
concerns different practice between countries. Healthcare
providers can be unaware of the guidelines and lack of
communication between healthcare providers. General
practitioners can also fail to perform the test or refer the
women to biochemical departments [8-10,27]. The patient
related barriers are lack of time and concerns about future
health [30]. Women can also be unaware of the risk of dia-
betes after gestational diabetes [8-10,27]. The fragmenta-
tion of care may also account for low participation since
this often leads to confusion about the responsibility for
follow-up screening [8-10,27,33]. Participation gives wo-
men a higher risk of diabetes diagnosis or treatment and
an increased possibility of early detection of diabetes or
initiation of treatment. The risk estimates were high at the
last controls possibly due to the attendance of women
who had been diagnosed or treated at earlier controls, al-
though their attendance also decreased over time. The
women who were not followed up were more likely to be
diagnosed at a later point, when their diabetes may have
progressed, since clinical diabetes can remain undiagnosed
for years [22]. The high risk of a diabetes diagnosis among
women attending controls and estimated undiagnosed
diabetes among non-attending women, lead us to believe
that a considerable number of the non-attenders can be
affected by diabetes after gestational diabetes. We found
the diabetes risk to increase with successive controls,
which is in accordance with findings from other studies
that show an increasing risk of diabetes within the first
five years after gestational diabetes [2]. Women with high
income had a significantly lower risk of diabetes diagnosis
or treatment. Socioeconomic factors are plausible reasons
for this, since they are one of the determinants for dia-
betes [23]. In view of the limitations described in previous
sections, our results should be interpreted with caution.
The main result of this study is the finding of low partici-
pation in follow-up screening after gestational diabetes,
except for the first control after giving birth. Our study
has demonstrated the importance of follow-up screening
of women to ensure early detection and initiation of treat-
ment for the prevention of late complications caused by
diabetes. Follow-up screening of these women is a con-
cern for public health as low participation impedes the de-
tection of diabetes in women with previous gestational
diabetes. This has been emphasized by a previous Danish
study, which found that two out of three diabetes cases in
the general population were undiagnosed [34]. The low
participation in follow-up screening after gestational dia-
betes may reflect an ignorance of the risk involved, or fail-
ure by health staff to refer the patient and unawareness of
guidelines [8-10]. Fragmented care is another possible fac-
tor since the care of women is organised between obstetri-
cians and general practitioners. The fragmentation can
contribute to lack of communication regarding the re-
commendations for follow-up screening and the women’s
future risk between the providers [8-10,33]. The study
provides clinicians with important knowledge of the risk
of diabetes among non-attending women and the need for
communicating the risk to the women in order to ensure
follow-up screening. In low-income countries, women
with pregnancy complicated by gestational diabetes face
greater barriers such as availability, affordability and ac-
cess to services, which concerns both screening during
pregnancy and access to follow-up screening [30].
What this study adds
In contrast to other studies examining participation in
follow-up screening [7,8,11,27,35], this study followed
women with previous gestational diabetes over several
screening rounds and examined the consequences of non-
attendance in follow-up screening. We document rapidly
declining participation in follow-up screening with time
and estimated that women not attending potentially can
have undiagnosed diabetes. This study also shows that
follow-up screening enables early detection of diabetes.
Our study furthermore demonstrates the great potential
of monitoring the quality of health care sectors through
national registers.
Suggestions for further research
Our study has documented the need for preventive health
interventions to ensure stringent follow-up screening of
women with prior gestational diabetes in order to ensure
the early detection of diabetes and initiation of treatment.
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The general lack of interventions to ensure participa-
tion in follow-up screening is described in other studies
[8,27,33,35]. Our findings may furthermore help in the de-
velopment of interventions to enhance participation in
follow-up screening. Possible interventions could concern
reduction of fragmented care and facilitation of other ef-
forts to improve participation in follow-up screening. Such
efforts could concern reminder systems, which has shown
to improve the participation in follow-up screening signifi-
cantly [8,11,35,36]. Such systems can have a positive im-
pact on the participation in follow-up screening [31].
Conclusion
In this study of women with prior first-time gestational
diabetes we found low participation rates in follow-up
screening, except for the first control after which it
decreased with time after giving birth. Women who did
not attend follow-up screening had a lower risk of
diabetes diagnosis or treatment and early detection of
diabetes. The higher possibility of early detection of dia-
betes among women attending follow-up screening re-
duces their risk of late complications. Contrary to national
and international guidelines [5,6], the majority of women
with gestational diabetes failed to return for follow-up
screening, which emphasizes the importance of interven-
tions to ensure early detection and prevention of diabetes
after gestational diabetes [8,11,35].
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